Search results
Showing 31 to 45 of 99 results for schizophrenia
Evidence-based recommendations on electroconvulsive therapy (ECT) for treating catatonia, prolonged or severe manic episodes or schizophrenia in adults.
Antenatal and postnatal mental health: clinical management and service guidance (CG192)
This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers depression, anxiety disorders, eating disorders, drug- and alcohol-use disorders and severe mental illness (such as psychosis, bipolar disorder and schizophrenia). It promotes early detection and good management of mental health problems to improve women’s quality of life during pregnancy and in the year after giving birth.
and schizophrenia:- What is the benefit of a CBT-based trauma reprocessing intervention on PTSD symptoms in people with psychosis and...
clinical effectiveness of clozapine for children and young people with schizophrenia with symptoms unresponsive to antipsychotic...
This quality standard covers clinical assessment, prioritising and managing healthcare for adults aged 18 years and over with 2 or more long-term health conditions (multimorbidity). At least 1 of these conditions must be a physical health condition. It describes high-quality care in priority areas for improvement.
alone, compared with treatment as usual, in people with psychosis or schizophrenia who choose not to take antipsychotic medication? Any...
Smoking: smoking status for people with long-term conditions (IND97)
This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM38
effectiveness of peer support interventions in people with psychosis and schizophrenia? Any explanatory notes(if applicable) Why this is...
Weight management: BMI recording (long term conditions) (IND320)
This indicator covers the percentage of patients with coronary heart disease, stroke or TIA, diabetes, at high risk of developing type 2 diabetes, hypertension, peripheral arterial disease, heart failure, COPD, dyslipidaemia, learning disability, obstructive sleep apnoea, schizophrenia, bipolar disorder or other psychoses who have had a BMI recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]
Topic prioritisation
This guideline covers optimising care for adults with multimorbidity (multiple long-term conditions) by reducing treatment burden (polypharmacy and multiple appointments) and unplanned care. It aims to improve quality of life by promoting shared decisions based on what is important to each person in terms of treatments, health priorities, lifestyle and goals. The guideline sets out which people are most likely to benefit from an approach to care that takes account of multimorbidity, how they can be identified and what the care involves.
Transcranial magnetic stimulation for auditory hallucinations (IPG680)
Evidence-based recommendations on transcranial magnetic stimulation for auditory hallucinations. This involves stimulating the brain with pulses of electromagnetic energy.
View recommendations for IPG680Show all sections
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
Bipolar, schizophrenia and other psychoses: target organ damage (IND86)
This indicator covers the percentage of patients on lithium therapy with a record of serum creatinine and TSH in the preceding 9 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM21
Smoking: current smokers (bipolar, schizophrenia and other psychoses) (IND27)
This indicator covers the proportion of people with severe mental illness who are recorded as current smokers. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG44